Published in Semin Oncol on December 01, 1985
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol (2009) 0.99
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol (2015) 0.89
Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs (2002) 0.84
Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Rep (2016) 0.82
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65
Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19
Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res (1991) 1.73
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51
Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol (2002) 1.43
Human melanocytes cultured from nevi and melanomas. J Invest Dermatol (1986) 1.36
Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am (1984) 1.30
SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene (2007) 1.29
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res (2000) 1.26
Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods (1992) 1.22
Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys (1998) 1.22
Interferons in the treatment of human cancer. J Clin Oncol (1984) 1.22
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A (2000) 1.19
Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol (2001) 1.14
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist (2000) 1.09
Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol (1997) 1.08
Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest (2000) 1.02
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer (2001) 1.02
Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res (1996) 1.01
Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. Cancer Res (1987) 1.00
Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med (1985) 0.98
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol (2010) 0.97
Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. Endocrinology (1984) 0.94
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res (1985) 0.94
Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun (1984) 0.94
An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol (1992) 0.93
Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol (1993) 0.93
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol (2012) 0.92
A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (1990) 0.92
Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial. Cancer Res (1980) 0.92
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer (1999) 0.91
Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections. Cytometry (1996) 0.90
Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma. Mol Med (1999) 0.90
Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res (2001) 0.89
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol (1997) 0.89
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin Cancer Res (1996) 0.89
Molecular analysis of melanoma precursor lesions. Cell Growth Differ (1996) 0.89
New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res (1996) 0.88
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol (1984) 0.88
Interferons in melanoma. Curr Opin Oncol (1996) 0.88
IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther (2006) 0.87
Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). J Clin Oncol (1987) 0.87
Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep (1984) 0.86
Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum. Cancer Res (1984) 0.86
Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med (1988) 0.85
Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol (2000) 0.84
Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg (1993) 0.84
A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol (1987) 0.83
Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol (1986) 0.83
Dysplastic nevi in association with multiple primary melanoma. Cancer Res (1988) 0.83
Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev (1984) 0.83
Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI. Br J Cancer (1991) 0.82
Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res (2000) 0.82
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer (2011) 0.82
A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma. Epidemiology (1991) 0.81
Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute. Melanoma Res (1993) 0.81
Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes. J Clin Invest (1985) 0.80
Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol (1994) 0.80
Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res (1992) 0.80
Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res (1996) 0.80
Effects of oral contraceptives and pregnancy on melanomas. N Engl J Med (1979) 0.80
Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther (2000) 0.80
Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med (1984) 0.79
Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma. Clin Exp Immunol (1991) 0.79
Analysis of two human monoclonal antibodies against melanoma. Int J Cancer (1992) 0.79
Adjuvant therapy of melanoma. Semin Surg Oncol (1998) 0.79
Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol (1996) 0.79
A role for suppressor T cells in immunological enhancement of tumor growth. Prog Exp Tumor Res (1974) 0.78
Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Clin Exp Immunol (1998) 0.78
Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals. J Clin Oncol (1989) 0.78
Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J Sci Am (2000) 0.78
Comparison of nonfamilial and familial melanoma. Dermatology (1992) 0.78
Vitiligo and melanoma: can genetically abnormal melanocytes result in both vitiligo and melanoma within a single family? J Am Acad Dermatol (1984) 0.78
Prognostic role of antibody reactivity to melanoma. J Clin Invest (1986) 0.78
Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials. J Biol Response Mod (1983) 0.78
A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer (1999) 0.78
Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Ann Surg Oncol (1995) 0.78
Interferons in the therapy of solid tumors. Oncology (1994) 0.77
Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells. J Immunother (1991) (1991) 0.77
Interclinician agreement on the recognition of selected gross morphologic features of pigmented lesions. Studies of melanocytic nevi V. J Am Acad Dermatol (1992) 0.77
Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am (1998) 0.77
Cytokine-based therapy for melanoma: pre-clinical studies. Forum (Genova) (2001) 0.77
Adjuvant application of interferons. Semin Oncol (1996) 0.77
Comparison of gallium-67 versus indium-111 monoclonal antibody (96.5, ZME-018) in detection of human melanoma in athymic mice. J Nucl Med (1987) 0.77
Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology (1992) 0.77
Immune response to autologous human melanoma: implication of class I and II MHC products. Biochim Biophys Acta (1986) 0.77
Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885. Invest New Drugs (1994) 0.77
Burden of illness associated with metastatic melanoma: an audit of 100 consecutive referral center cases. Cancer (2001) 0.77
Targeted therapy for malignant melanoma. Curr Oncol Rep (2001) 0.77